[Form 4] Aptevo Therapeutics Inc Insider Trading Activity
Aptevo Therapeutics Inc. (APVO) reports that Daphne Taylor, the company's SVP and Chief Financial Officer, acquired 11,500 Restricted Stock Units (RSUs) on 08/06/2025. The filing shows these RSUs convert one-for-one into common stock and are recorded as a direct holding following the reported transaction.
The RSUs carry a $0 price in the filing and vest in full on the first anniversary of the grant, meaning they will convert into 11,500 common shares when vested. The form reflects an insider equity grant reported under Form 4 and does not disclose the company鈥檚 total outstanding shares, so the percentage dilution from this grant cannot be determined from this filing alone.
Aptevo Therapeutics Inc. (APVO) comunica che Daphne Taylor, SVP e Chief Financial Officer della societ脿, ha acquisito 11.500 Restricted Stock Units (RSU) il 08/06/2025. La comunicazione indica che queste RSU si convertono una a una in azioni ordinarie e sono registrate come una partecipazione diretta a seguito della transazione riportata.
Nel documento le RSU risultano con un prezzo di $0 e maturano per intero al primo anniversario della concessione, pertanto si convertiranno in 11.500 azioni ordinarie al momento della maturazione. Il modulo riflette una concessione di equity da parte di un insider segnalata con il Modulo 4 e non indica il numero totale di azioni in circolazione della societ脿, quindi la percentuale di diluizione derivante da questa concessione non pu貌 essere determinata solo da questo documento.
Aptevo Therapeutics Inc. (APVO) informa que Daphne Taylor, la SVP y directora financiera de la compa帽铆a, adquiri贸 11.500 Restricted Stock Units (RSU) el 08/06/2025. El informe se帽ala que estas RSU se convierten una a una en acciones ordinarias y se registran como una participaci贸n directa tras la operaci贸n comunicada.
En el formulario las RSU aparecen con un precio de $0 y vencen 铆ntegramente al primer aniversario de la concesi贸n, por lo que se convertir谩n en 11.500 acciones ordinarias cuando se liberen. El documento refleja una concesi贸n de capital por parte de un insider reportada en el Formulario 4 y no divulga el n煤mero total de acciones en circulaci贸n de la compa帽铆a, por lo que la diluci贸n porcentual derivada de esta concesi贸n no puede determinarse a partir de este informe.
Aptevo Therapeutics Inc. (APVO)電� 須岇偓鞚� SVP 瓴� 斓滉碃鞛毂呾瀯鞛�(CFO)鞚� Daphne Taylor臧� 2025雲� 08鞗� 06鞚检棎 11,500臧滌潣 Restricted Stock Units(RSU)毳� 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 鞚� RSU電� 1雽赌1搿� 氤错喌欤茧 鞝勴櫂霅橂┌, 頃措嫻 瓯半灅 鞚错泟 歆侅爲 氤挫湢搿� 旮半霅橃柎 鞛堨姷雼堧嫟.
靹滊靸� RSU鞚� 臧�瓴╈潃 $0搿� 響滉赴霅橃柎 鞛堦碃, 攵�鞐澕 旮办 1欤茧厔 霑� 鞝勳暋 氩犾姢韺�(甓岆Μ 頇曥爼)霅橃柎 氩犾姢韺� 鞁滌爯鞐� 11,500欤检潣 氤错喌欤茧 鞝勴櫂霅╇媹雼�. 鞚� 鞏戩嫕鞚� Form 4鞐� 氤搓碃霅� 雮措秬鞛� 歆�攵� 攵�鞐ゼ 氚橃榿頃� 瓴冹溂搿� 須岇偓鞚� 齑� 氚滍枆欤检嫕靾橂姅 瓿店皽霅橃 鞎婌晞 鞚措矆 攵�鞐 鞚疙暅 歆�攵� 頋劃毳犾潃 鞚� 靹滊毵岇溂搿滊姅 韺岇晠頃� 靾� 鞐嗢姷雼堧嫟.
Aptevo Therapeutics Inc. (APVO) rapporte que Daphne Taylor, vice-pr茅sidente senior et directrice financi猫re de la soci茅t茅, a acquis 11 500 Restricted Stock Units (RSU) le 08/06/2025. Le dossier indique que ces RSU se convertissent une action pour une en actions ordinaires et sont inscrites comme une participation directe suite 脿 la transaction d茅clar茅e.
Dans le formulaire, les RSU sont indiqu茅es avec un prix de 0 $ et deviennent enti猫rement acquises au premier anniversaire de l'attribution, ce qui signifie qu'elles se convertiront en 11 500 actions ordinaires lors de leur acquisition. Le formulaire refl猫te une attribution d'actions d'initi茅 d茅clar茅e sur le Formulaire 4 et ne divulgue pas le nombre total d'actions en circulation de la soci茅t茅, de sorte que le pourcentage de dilution r茅sultant de cette attribution ne peut 锚tre d茅termin茅 脿 partir de ce seul document.
Aptevo Therapeutics Inc. (APVO) meldet, dass Daphne Taylor, SVP und Chief Financial Officer des Unternehmens, am 08/06/2025 11.500 Restricted Stock Units (RSUs) erworben hat. Die Einreichung zeigt, dass diese RSUs eins zu eins in Stammaktien umgewandelt werden und nach der gemeldeten Transaktion als direkte Beteiligung verzeichnet sind.
Im Formular sind die RSUs mit einem Preis von $0 angegeben und vollst盲ndig am ersten Jahrestag der Gew盲hrung f盲llig, das hei脽t, sie werden bei F盲lligkeit in 11.500 Stammaktien umgewandelt. Das Formular stellt eine Insider-Aktienzuteilung dar, die in Formular 4 gemeldet wurde, und enth盲lt keine Angabe zur Gesamtzahl der ausstehenden Aktien des Unternehmens, sodass die prozentuale Verw盲sserung durch diese Zuteilung aus dieser Einreichung allein nicht ermittelt werden kann.
- 11,500 RSUs were granted to the SVP/CFO and are documented transparently in a Form 4 filing.
- Vesting schedule is explicit: the RSUs vest in full on the first anniversary of the grant, providing clear timing for conversion.
- RSUs listed at $0 will convert into 11,500 common shares upon vesting, increasing the share count when they vest.
- Materiality cannot be assessed from this filing because it does not disclose total outstanding shares or the reporting person's prior holdings.
Insights
TL;DR: Executive received 11,500 RSUs that vest in one year; routine equity grant with clear vesting but limited immediate disclosure on materiality.
The Form 4 documents a direct acquisition of 11,500 RSUs by Daphne Taylor, SVP and CFO, converting one-for-one into common stock. The grant is structured with a single-date full-vesting schedule (vests in full on the first anniversary of grant), which provides straightforward alignment of executive and shareholder timing but also creates a defined future issuance event. The filing includes the $0 price characteristic of RSUs and an attorney-in-fact signature; it does not provide information on outstanding share count or prior holdings for Taylor, so governance impact is limited to disclosure of the award rather than showing material ownership change.
TL;DR: The RSU grant creates potential conversion into 11,500 shares; without outstanding share data the market impact cannot be quantified from this filing.
This Form 4 reports an acquisition of 11,500 derivative securities (Restricted Stock Units) that will convert to 11,500 shares of common stock when vested. The instrument carries a $0 conversion price and is held directly. From a securities perspective the event is an issuance over time rather than a sale by the insider. The filing lacks context on total shares outstanding and any prior insider holdings, so the size of this grant relative to market capitalization or float is not determinable here, limiting any assessment of dilution or market impact.
Aptevo Therapeutics Inc. (APVO) comunica che Daphne Taylor, SVP e Chief Financial Officer della societ脿, ha acquisito 11.500 Restricted Stock Units (RSU) il 08/06/2025. La comunicazione indica che queste RSU si convertono una a una in azioni ordinarie e sono registrate come una partecipazione diretta a seguito della transazione riportata.
Nel documento le RSU risultano con un prezzo di $0 e maturano per intero al primo anniversario della concessione, pertanto si convertiranno in 11.500 azioni ordinarie al momento della maturazione. Il modulo riflette una concessione di equity da parte di un insider segnalata con il Modulo 4 e non indica il numero totale di azioni in circolazione della societ脿, quindi la percentuale di diluizione derivante da questa concessione non pu貌 essere determinata solo da questo documento.
Aptevo Therapeutics Inc. (APVO) informa que Daphne Taylor, la SVP y directora financiera de la compa帽铆a, adquiri贸 11.500 Restricted Stock Units (RSU) el 08/06/2025. El informe se帽ala que estas RSU se convierten una a una en acciones ordinarias y se registran como una participaci贸n directa tras la operaci贸n comunicada.
En el formulario las RSU aparecen con un precio de $0 y vencen 铆ntegramente al primer aniversario de la concesi贸n, por lo que se convertir谩n en 11.500 acciones ordinarias cuando se liberen. El documento refleja una concesi贸n de capital por parte de un insider reportada en el Formulario 4 y no divulga el n煤mero total de acciones en circulaci贸n de la compa帽铆a, por lo que la diluci贸n porcentual derivada de esta concesi贸n no puede determinarse a partir de este informe.
Aptevo Therapeutics Inc. (APVO)電� 須岇偓鞚� SVP 瓴� 斓滉碃鞛毂呾瀯鞛�(CFO)鞚� Daphne Taylor臧� 2025雲� 08鞗� 06鞚检棎 11,500臧滌潣 Restricted Stock Units(RSU)毳� 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 鞚� RSU電� 1雽赌1搿� 氤错喌欤茧 鞝勴櫂霅橂┌, 頃措嫻 瓯半灅 鞚错泟 歆侅爲 氤挫湢搿� 旮半霅橃柎 鞛堨姷雼堧嫟.
靹滊靸� RSU鞚� 臧�瓴╈潃 $0搿� 響滉赴霅橃柎 鞛堦碃, 攵�鞐澕 旮办 1欤茧厔 霑� 鞝勳暋 氩犾姢韺�(甓岆Μ 頇曥爼)霅橃柎 氩犾姢韺� 鞁滌爯鞐� 11,500欤检潣 氤错喌欤茧 鞝勴櫂霅╇媹雼�. 鞚� 鞏戩嫕鞚� Form 4鞐� 氤搓碃霅� 雮措秬鞛� 歆�攵� 攵�鞐ゼ 氚橃榿頃� 瓴冹溂搿� 須岇偓鞚� 齑� 氚滍枆欤检嫕靾橂姅 瓿店皽霅橃 鞎婌晞 鞚措矆 攵�鞐 鞚疙暅 歆�攵� 頋劃毳犾潃 鞚� 靹滊毵岇溂搿滊姅 韺岇晠頃� 靾� 鞐嗢姷雼堧嫟.
Aptevo Therapeutics Inc. (APVO) rapporte que Daphne Taylor, vice-pr茅sidente senior et directrice financi猫re de la soci茅t茅, a acquis 11 500 Restricted Stock Units (RSU) le 08/06/2025. Le dossier indique que ces RSU se convertissent une action pour une en actions ordinaires et sont inscrites comme une participation directe suite 脿 la transaction d茅clar茅e.
Dans le formulaire, les RSU sont indiqu茅es avec un prix de 0 $ et deviennent enti猫rement acquises au premier anniversaire de l'attribution, ce qui signifie qu'elles se convertiront en 11 500 actions ordinaires lors de leur acquisition. Le formulaire refl猫te une attribution d'actions d'initi茅 d茅clar茅e sur le Formulaire 4 et ne divulgue pas le nombre total d'actions en circulation de la soci茅t茅, de sorte que le pourcentage de dilution r茅sultant de cette attribution ne peut 锚tre d茅termin茅 脿 partir de ce seul document.
Aptevo Therapeutics Inc. (APVO) meldet, dass Daphne Taylor, SVP und Chief Financial Officer des Unternehmens, am 08/06/2025 11.500 Restricted Stock Units (RSUs) erworben hat. Die Einreichung zeigt, dass diese RSUs eins zu eins in Stammaktien umgewandelt werden und nach der gemeldeten Transaktion als direkte Beteiligung verzeichnet sind.
Im Formular sind die RSUs mit einem Preis von $0 angegeben und vollst盲ndig am ersten Jahrestag der Gew盲hrung f盲llig, das hei脽t, sie werden bei F盲lligkeit in 11.500 Stammaktien umgewandelt. Das Formular stellt eine Insider-Aktienzuteilung dar, die in Formular 4 gemeldet wurde, und enth盲lt keine Angabe zur Gesamtzahl der ausstehenden Aktien des Unternehmens, sodass die prozentuale Verw盲sserung durch diese Zuteilung aus dieser Einreichung allein nicht ermittelt werden kann.
FAQ
What did Daphne Taylor (APVO) acquire according to the Form 4?
What is Daphne Taylor's position at Aptevo (APVO)?
When do the RSUs vest and convert to common stock?
Did the reporting person pay for the RSUs?
How many common shares will the RSUs convert into?
